uma borate: evaluating mbg453 in high-risk mds and aml
Published 4 years ago • 714 plays • Length 4:32Download video MP4
Download video MP3
Similar videos
-
7:28
mbg453 with hypomethylating agents in aml and high-risk mds
-
7:45
acute myeloid leukemia: highlights of the presentation by dr uma borate from ash 2023 symposium
-
5:36
david sallman: magrolimab plus azacitidine effective in mds and aml
-
2:28
meet uma borate, md, msc, hematologist at the osuccc – james
-
5:15
high-risk mds/aml: genomic-driven approaches from ash19 - eytan stein, md
-
4:19
evaluating the magrolimab-based triplet combination in high-risk aml
-
1:02:28
what are the current treatment options for aml
-
1:27:42
precision medicine in mds and aml
-
34:15
from mds to aml: what every patient needs to know 11/28/17
-
0:48
what is the cause of mds? #aml
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
5:55
what are the most important and recent advances made in aml treatment?
-
1:24
antibodies for the treatment of mds: magrolimab & sabatolimab
-
3:08
ash clinical practice guidelines for the treatment of older adults with aml
-
2:06
onvansertib with cytarabine or decitabine for r/r aml
-
5:52
geoffrey l. uy, md: investigating flotetuzumab in aml and mds
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
4:31
emerging immunotherapy modalities in aml and exciting data from ash 2019
-
8:32
is there synergy between anti-tim-3 therapy and hmas in the treatment of mds?